Built all 18 planned pages: diagnosis; epidemiology; airway biology; genetics/environment/prevention; phenotypes/endotypes/treatable traits; mild/moderate disease; severe asthma/biologics; exacerbations; inhaler technique/adherence/self-management; children; pregnancy; comorbidity/mimics; guidelines; biomarkers; trials; patient experience; safety; and the expanded overview.
Page depth: every wiki page is 150–400 lines. Seventeen pages carry 25–32 unique PubMed citations; the trials landscape carries 16 PubMed citations plus 15 live-verified ClinicalTrials.gov records.
Literature layer: generated a 394-record master bibliography with page provenance; wrote six landmark-study notes; built current guideline and quantitative-statistics registries; and added a four-file patient-voice layer with public-source ethics, organization verification and a two-source minimum for themes.
Research frontier: replaced the seed list with 24 stable, tiered open questions and a 14-row “Dots not yet connected” junction table.
Live literature work: ran broad and focused PubMed E-utilities searches across every page domain, then resolved every cited PMID from the live records cache before use. Queried ClinicalTrials.gov API v2 across six asthma trial searches, yielding 482 unique live records used to verify every cited NCT ID.
Current guidance checked live: GINA 2026 Strategy and Summary Guide; BTS/NICE/SIGN NG245; NHLBI/NAEPP 2020 focused updates; Australian Asthma Handbook v3.0; and WHO PEN.
Preventive citation control: an exact-ID PubMed check exposed several plausible but unrelated recalled PMIDs. They were excluded, and final validation now compares every PMID to live metadata, every NCT to the live ClinicalTrials.gov cache, inline author/year to PubMed authorship, and in-text citations to each page's reference list.
Could not verify / coverage limits: the English-language patient-organization search did not establish representative coverage for Africa, South Asia, Latin America or most of continental Europe, so no absence claim was made. Registry recruitment status was treated as provisional, and this build did not independently audit every quantitative claim against full text; that remains the required separate audit.
Verification: 18/18 planned pages exist; 394/394 unique wiki PMIDs resolve in the session cache; 15/15 NCT IDs resolve in the session API cache; all local Markdown links resolve; all in-text PMID citations have corresponding page references; and asthma is marked built in the roadmap.
Next: independent citation/content audit before any page status moves from draft to curated.
Scope completed: audited 18/18 wiki pages and every asthma literature artifact: the 401-record bibliography, six landmark notes, guideline registry, statistics register, and four patient-voice files.
Citation volume checked: re-fetched all 401 unique PMIDs through live PubMed E-utilities summary and full-record queries and reviewed 1,645 pre-audit PMID occurrences in context. After bibliography and evidence-gap corrections, the condition contains 1,707 exact PMID occurrences; all resolve to the same 401 live records and every wiki in-text PMID has a matching page reference.
Trial-registry volume checked: re-fetched all 15 originally cited NCT records individually through ClinicalTrials.gov API v2. Focused repeat searches added four relevant records, producing a final set of 19/19 individually resolved NCT IDs.
Errors found and fixed: 10 discrete citation/content issues. Seven live-verified guideline PMIDs used by the condition were absent from the master bibliography and were added. One asthma-death uncertainty interval could not be reproduced from the cited live record and was removed while retaining the supported point estimate with a caveat. One stale statement implying no biologic-withdrawal trial was corrected after NCT06818019 was found. One pregnancy evidence-gap statement was sharpened after live records for omalizumab, dupilumab and benralizumab pregnancy-exposure studies were found (NCT00373061, NCT04173442 and NCT03794999).
Absence claims re-searched: repeated live searches for direct biologic comparisons, biologic withdrawal, type-2-low targeted therapy, primary prevention, biologics in pregnancy, diagnostic test combinations, biomarker validation, social-media harm evidence, digital-monitoring mortality and low-resource AIR/MART implementation. Claims were converted to dated descriptions of what the searches did find and what outcome evidence remains missing; no claim of universal nonexistence remains.
External-source checks: rechecked the current GINA, BTS/NICE/SIGN, NHLBI/NAEPP, Australian Asthma Handbook and WHO sources, plus every patient-organization source used in the patient-voice layer. Access/verification dates were synchronized to 2026-08-30.
Remaining flags: none. No unresolved verification marker, unresolved PMID/NCT identifier, broken local Markdown link, unmatched wiki citation or substantive audit issue remains.
Promotion decision: all 18 pages passed. Every wiki page is now status: curated with last-curated: 2026-08-30; the master index and roadmap are audited.
Final validation: page lengths remain within the required 150–400-line range (167–230 lines); all required TL;DR, open-question, related-page and reference sections are present; 401/401 exact PMIDs and 19/19 exact NCT IDs resolve live; all 401 bibliography identifiers cover the condition corpus; and all local links resolve.
2026-10-15 — Periodic literature sweep (author: Claude; independent audit pending)¶
Window and query record: PubMed E-utilities, publication dates 2026-08-28 to 2026-10-15 ([dp]), across 18 topic queries: diagnosis, burden, immunobiology, genetics/environment, phenotypes, mild/moderate treatment, severe/biologics, exacerbations, adherence/self-management, children, pregnancy, comorbidity, guidelines, biomarkers, trials, patient experience, safety, and systematic reviews. A broad asthma[ti] query added 718 records. In total 825 distinct records were resolved by esummary. Every topic was re-run as a "Cochrane Database Syst Rev"[jour] query, with broad CDSR checks by publication, entry and MeSH date. Exact strings, translations, IDs and per-record checks are in the sweep manifest.
Cochrane: the only CDSR record in the window is a protocol, not a review: systemic azoles for asthma with fungal sensitisation (Fukuda 2026, PMID 42813456). No new or updated Cochrane review supersedes or contradicts anything this condition asserts, and that absence is in PubMed only. cochranelibrary.com returned HTTP 403, so CENTRAL was not searched.
Beyond PubMed: Europe PMC REST was queried for 13 topic strings plus a non-MEDLINE-only query (51 hits: 26 PMC-only, 25 preprints). None was promoted to a citation, so no DOI-only record needed Crossref resolution. ClinicalTrials.gov API v2 re-fetched all 19 tracked NCT records, plus NIMBLE (NCT04718389), PERFORM (NCT06372496), and four intervention searches for GLP-1 agonists in asthma. The ISRCTN API was queried for asthma (1,245 records; the 100 most recent inspected). WHO ICTRP is JS-driven and was not searched programmatically. Guideline pages were retrieved for NICE NG245 (history), the Australian Asthma Handbook (still V3.0) and NHLBI (last updated 2021-02-04); no new edition was found. ginasthma.org returned HTTP 403. The WHO asthma fact sheet (dated 2026-04-28) was retrieved. Patient-organization pages retrieved: AAFA, Allergy & Asthma Network, GAAPP and the Asthma + Lung UK home page. Asthma Australia and Asthma Canada news pages returned 403, and the Asthma + Lung UK news URL returned 404. SciELO/LILACS were not searched (HTTP 403 per SOURCES.md), so no claim about Latin American evidence is made (see OQ-24). Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset; Crossref was queried without mailto.
Retraction and access checks: none of the 23 newly cited PMIDs carries a PubMed Retracted Publication or Expression of Concern type, and all have empty Crossref updated-by lists except Hodkinson 2020 (one correction, the erratum it replaces). A live re-resolution of all 420 condition PMIDs found none unresolved or retracted. Full text was opened for Couillard 2026 (PMC13623818) and PERFORM (PMC13619735), and their figures were checked against text and tables. All other new claims are labelled "abstract-level" on the page, because Europe PMC lists them as subscription-only or the PMC record did not serve full text.
What survived triage (new evidence):
FeNO diagnostic meta-analysis with primary-care validation: Roy 2026, PMID 42743935. Added to biomarkers and diagnosis.
Symptom burden versus type-2 biomarkers for attack prediction: Couillard 2026, PMID 42624803. Added to biomarkers.
GRADE macrolide meta-analysis showing similar effects in T2-high and T2-low asthma: Ologundudu 2026, PMID 41654262. Added to trials.
Remission Delphi: Couillard 2026, PMID 42463041. PERFORM remission RCT: Noorduyn 2026, PMID 42474701. Both added to trials.
NIMBLE switch trial (Chupp 2026, PMID 41738176; published May 2026 and missed at build, found via an in-window editorial) and the depemokimab indirect comparison (Bourdin 2026, PMID 42173441). Added to severe asthma.
EAACI cumulative systemic-steroid harm meta-analysis: Scheire 2026, PMID 42011838. Added to red flags.
CHEST-Africa prevalence (Ozoh 2026, PMID 42744587) and the 2025–2050 macroeconomic burden model (Cao 2026, PMID 42520825). Added to epidemiology.
GLP-1 systematic review (Saadat 2026, PMID 42167405), the GATA-3 semaglutide RCT (NCT05254314; primary completion 2026-09-28, no results) and the WRAPT tirzepatide RCT (ISRCTN91904759, registered 2026-09-21). Added to trials.
IDD smart-inhaler pilot RCT: Park 2026, PMID 42413691. Added to trials.
GINA 2026 executive summary (PMID 42847657) and EAACI pollen GRADE guideline (PMID 42359506). Added to the registry.
Patient voice: the AAFA 2026 Asthma Capitals report.
Most of the 825 records deserved nothing. No paper warranted a landmark note.
Trial status changes:NCT06818019 (dupilumab withdrawal) and NCT07746921 (IDD smart inhaler) moved from not yet recruiting to recruiting. No tracked trial posted results. NCT06748053 passed its primary completion date (2026-07-14) without results.
Pre-existing errors found and fixed:
Reference metadata: 84 reference lines on 17 pages (77 distinct PMIDs) named the wrong journal, often with volume and pages that do not exist for the cited record. Examples: Boparai 2024 was listed as "Med Clin North Am. 2024;108:1-16" but is Otolaryngol Clin North Am 57(2):201-213; Hodkinson's network meta-analysis was cited through its erratum. In every case the PMID, first author and year matched PubMed, so the claims point at the right records. The journal/year/volume/pages segment of each line was rewritten from live PubMed esummary; the full list is in the manifest. Four lines with the same fault had been fixed by hand earlier in the session: Armeftis on two pages, He, and Malinovschi. The registry's first author for PMID 38408152 was corrected from Seidman to Gurgel.
Citations that did not support their sentence: the ipratropium sentence in exacerbations cited two letters (PMIDs 10866596, 10650243). They were replaced by Rodrigo 1999 (10527039), Stoodley 1999 (10381989), Griffiths 2013 Cochrane (23966133) and Vézina 2014 Cochrane (25080126), and the sentence now carries their figures. The patient-experience page cited the erratum notice 37500118 as a network meta-analysis; it was replaced by the original, Hodkinson 2020 (32816816). The children page called a 3-page Paediatr Respir Rev summary (25164572) "a Cochrane review"; it was replaced by the Cochrane review itself, Zhang 2014 (25030198), whose abstract supports the sentence as written. The bibliography was updated accordingly: 4 entries replaced, 420 records total.
The 2026-08-30 audit's statement that all reference lines and citations were verified did not hold for journal metadata or for these four citations.
Changed:
Content edits, now status: draft:wiki/biomarkers.md, diagnosis-and-objective-testing.md, severe-asthma-and-biologics.md, clinical-trials-landscape.md, red-flags-and-safety-concerns.md, epidemiology-and-global-burden.md, exacerbations-and-acute-care.md, asthma-in-children.md and patient-experience-and-advocacy.md.
Reference metadata only, verified against live PubMed, still curated: airway immunobiology, genetics/environment, guidelines, inhaler technique, mild/moderate, overview, phenotypes and pregnancy. This keep-curated call is a judgment the auditor may overrule.
Untouched: comorbidity and mimics.
Literature layer: updated BIBLIOGRAPHY.md, guidelines/REGISTRY.md, statistics/STATISTICS.md (WHO 363M/442k shown beside GBD 2021, not reconciled), patient-voice/organizations.md and patient-voice/sources.md.
Open questions: sharpened OQ-1, -3, -7, -8, -13, -14, -16, -17, -18 and -24; none closed.
Updated INDEX.md.
Next sweep / audit should chase:
An independent audit (different engine) of the nine draft pages and the 84 metadata rewrites.
Claim-level checks of the remaining PMIDs that resolve to editorials or short reviews but support opinion-type statements: 18797736, 38336438, 33529689, 25445824, 41412710, 22825384, 31422031 and 35818140.
Reference-line titles are paraphrased rather than PubMed titles on many pages.
GATA-3 (NCT05254314) results, and WRAPT's recruitment start.
The full AAAAI/ACAAI severe-asthma practice parameters, which the macrolide review was written for.
Full text of Roy 2026 and Scheire 2026, if access opens.
Paediatric validation of the FeNO thresholds.
A completed Cochrane review on systemic azoles (protocol 42813456).
GINA documents, once ginasthma.org is reachable.
Continue to qualify regional-evidence absences while SciELO/LILACS and CENTRAL remain unreachable.
2026-10-22 — Periodic literature sweep (author: Codex; independent audit pending)¶
Window and search record: 2026-08-28 through 2026-10-22, inclusive. Ran 18 major-topic PubMed E-utilities searches (diagnosis, burden, immunobiology, genetics/environment, phenotypes, mild/moderate treatment, severe/biologics, exacerbations, adherence/self-management, children, pregnancy, comorbidity, guidelines, biomarkers, trials, patient experience, safety and systematic reviews), paired each with a CDSR journal query, added three broad CDSR date-field checks and a broad asthma-title search: 40 queries, 898 distinct records retrieved by live efetch (896 journal-article records and two off-topic book records). Seventy-four IDs were not in the previous sweep’s search results. Exact queries, PubMed translations, returned IDs, registry snapshots, source-access outcomes, retraction checks and claim/table provenance are in the sweep manifest. A further 404 existing-corpus identifiers were re-resolved by esummary; this was identifier checking, not a claim-level audit of inherited content.
Cochrane first: the only in-window CDSR hit remains Fukuda’s systemic-azole protocol (PMID 42813456), not a completed review. No new completed/updated asthma Cochrane review was retrieved in these PubMed queries. This is a PubMed finding only: Cochrane Library/CENTRAL was not searched because SOURCES.md documents HTTP 403.
Beyond PubMed: queried Europe PMC REST separately for all 18 topics, plus a broad asthma query and a non-MEDLINE query, with complete cursor pagination: 3,982 unique records (3,181 MED, 668 PMC, 133 PPR); the non-MEDLINE query returned 801. Screened the 77 no-PMID-in-response records with asthma in the title. Europe PMC’s PMC-only responses can omit a PMID that PubMed already has: DIVA was reconciled to its live PubMed record by title, DOI and the full-text article identifier, despite a failed exact-phrase title query. No DOI-only paper or preprint was selected, so no DOI-only citation needed Crossref resolution.
Non-US registries: ISRCTN’s asthma API query returned 1,246 matches; inspected the first 100 and re-fetched WRAPT (ISRCTN91904759) individually. It still lists recruitment starting 2026-11-09, with its last update 2026-10-09. WHO ICTRP returned readable server-rendered asthma results this time (174 records for 160 trials shown); inspected the first 10 results only, without a completeness claim. Queried the German EudraCT TIPP record (2021-000190-81): it displays “Temporarily Halted,” while the publication describes the trial ending in March 2025. Preserve that discrepancy for follow-up rather than inferring current recruitment from either source alone.
What survived triage: five bibliography additions, taking the bibliography to 425 distinct PMIDs. Srivali 2026’s biologic-withdrawal review (PMID 42899551; published 20 October) and Germain 2026’s Medicare mepolizumab–dupilumab cohort (PMID 42886433; 16 October) are newly returned records since the last sweep. Li’s prediction-model review (PMID 42827866), Ducharme’s DIVA trial (PMID 42871976) and Zielen’s TIPP trial (PMID 42733757) are within-window catch-ups that the preceding search had returned but not catalogued. Most hits warranted no addition. Reliever meta-analyses largely corroborated covered evidence; formulation trials, exploratory challenge studies, preclinical work and small qualitative studies did not warrant new wiki claims. No landmark note was warranted.
Source-checked clinical changes: added Li’s full-text finding that six of eight model reports had high overall PROBAST risk of bias (Table 7), qualifying model readiness in biomarkers and OQ-7. Added DIVA’s imprecise rescue-OCS result (IRR 0.95, 95% CI 0.70–1.30; Table 2), with the 323-versus-865 recruitment shortfall, to children and statistics; OQ-5 now explicitly distinguishes preventing attacks from preventing asthma onset. Germain’s full-text limitations sharpen OQ-16 about the applicability of observational comparisons to older patients; no universal biologic ranking was added. TIPP remains bibliography-only. Srivali remains bibliography-only because its publisher full text returned 403; abstract effect estimates were not promoted into the wiki or the withdrawal question.
Retraction and full-text checks: all five added papers were checked against live PubMed publication types/comments and Crossref updated-by; none had a retraction/expression-of-concern signal and all five Crossref lists were empty. Opened full text for Li, DIVA and TIPP through Europe PMC XML and for Germain on the publisher’s site, checking the cited tables/limitations. The manifest records short source quotations and the locations behind new claims. Europe PMC called Germain subscription-only, but publisher HTML served the full text. Roy remains subscription-only in Europe PMC; Scheire’s full-text XML endpoint returned HTTP 500. Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset; Crossref received no owner email or mailto.
ClinicalTrials.gov: re-fetched all 22 currently cited IDs through API v2. No recruitment-status changes or new results postings were found versus 15 October; NIMBLE and PERFORM already had results posted. NCT06902766 was updated on 16 October: estimated primary completion moved from January to July 2027; it remains recruiting with no posted results. GATA-3 (NCT05254314) and the anti-TSLP dose-finding study (NCT06748053) still have no posted results. Dupilumab withdrawal (NCT06818019) remains recruiting with no results. DIVA’s trial identifier was also verified directly against API v2 for study identity; it is not newly tracked in the wiki.
Guidelines: retrieved GINA’s reports page (now reachable), NICE NG245 history, Australian Handbook changes (still V3.0), NHLBI (still the 2020 focused updates) and AAAAI’s current-parameter list. No newer comprehensive edition was identified on those pages. Added the missed WHO childhood asthma/bronchiolitis guideline, 7 May 2026, as an explicitly out-of-window catch-up; scope was verified from the official publication page, without re-auditing its recommendation tables. Separately recorded WHO’s 17 September announcement that primary-care asthma guidance is due in early 2027. The AAAAI list did not expose the anticipated severe-asthma parameter; the JTF site was a JavaScript shell, so the publication question remains open.
Statistics and patient organizations: rechecked WHO’s fact sheet (still the April 2026 page with 2023 estimates). Added CDC’s 2023 NHIS prevalence table, 2025 NHIS FastStats prevalence and 2024 NVSS mortality, preserving observation years and methods. Direct CDC requests returned 403 but web-tool retrieval succeeded; used the live opened page, not its stale search excerpt. Retrieved AAFA peak-season material, Allergy & Asthma Network news, GAAPP news, Asthma Australia’s media page and Asthma + Lung UK’s dated health-information advice; added one annotation for the latter. Asthma Canada news returned 403. No private patient details, new single-source theme or claim of intervention effectiveness was added.
Regional limits: SciELO and LILACS could not be searched (HTTP 403 documented in SOURCES.md, not re-probed); no unqualified conclusion about regional transportability or absence of regional studies is drawn. CENTRAL, Embase, Scopus and Web of Science were not searched. The WHO/ISRCTN partial scans do not establish trial completeness.
Files changed: biomarkers, children, trials landscape and guidelines wiki pages; bibliography; guideline registry; statistics register; patient-voice source register; OPEN-QUESTIONS; INDEX; this log; and the legal dated sweep manifest. All four edited wiki pages have last-curated: 2026-10-22 and status: draft; guidelines is newly demoted. The condition now has eight curated and ten draft pages. Prior audit issues remain pending; no page was promoted and no independent audit is claimed.
Verification: mechanical/source-provenance checks passed: all new-text identifiers resolve in this session’s live caches; five new bibliography records have both retraction checks; four source quotations match retrieved full text; four edited wiki pages have draft status/current dates and matching inline/reference identifiers; 425 distinct bibliography PMIDs; 100 relative links resolve, including 99 Markdown/JSON targets covered by the publisher’s path mapping. The manifest maps to the published sweeps/2026-10-22.json path. No global build, publishing script or git command was run. This does not replace the separate clinical audit.
Next sweep / independent audit: audit the October sweep changes and retain the 15 October metadata/citation audit queue; obtain Srivali’s withdrawal-review full text before synthesizing its pooled effects; reconcile TIPP’s EudraCT status with the published trial; monitor GATA-3 and anti-TSLP results, dupilumab withdrawal, WRAPT recruitment and the digital trial’s July 2027 milestone; chase the severe-asthma practice parameter through a readable JTF/publication source; check the forthcoming WHO primary-care guideline in early 2027; retry Roy/Scheire full text and continue qualifying regional-evidence limitations. OQ-5, -7 and -16 were sharpened, OQ-17’s registry observation refreshed, and no question was closed.
2026-10-29 — Periodic literature sweep (author: Grok; independent audit pending)¶
Window and query record: 2026-08-28 through 2026-10-29, inclusive, as specified. Ran the same 18 major-topic PubMed E-utilities searches as the prior two October sweeps, each paired with a "Cochrane Database Syst Rev"[jour] companion, plus three broad CDSR date-field checks and asthma[ti] with the date window: 40 queries, 1,009 distinct records by live esummary (111 not in the 2026-10-22 search-result set). Exact strings, translations, IDs, new-record titles, registry snapshots, source-access outcomes and retraction checks are in the sweep manifest.
Cochrane first: the only in-window CDSR hit remains Fukuda’s systemic-azole protocol (PMID 42813456), not a completed review. No new completed or updated asthma Cochrane review was retrieved in these PubMed queries. This is a PubMed finding only: Cochrane Library/CENTRAL was not searched (SOURCES.md, HTTP 403).
Beyond PubMed: queried Europe PMC REST for all 18 topics plus a broad asthma query and a non-MEDLINE query. Hit counts ranged from 336 (trials) to 4,710 (broad); pagination was capped on the large topics, so those counts are complete while the retrieved sets are not. Lite responses listed 661 unique records without a PMID in the payload (562 PMC, 99 preprints); many PMC-only hits already have PubMed records (DIVA is one example). No DOI-only paper or preprint was selected, so no DOI-only citation needed Crossref resolution. ISRCTN API: WRAPT (ISRCTN91904759) still lists recruitment 2026-11-09 to 2027-10-31, last updated 2026-10-09; an asthma query returned totalCount 269. WHO ICTRP portal loaded (HTTP 200) but the Condition=asthma search URL did not return a server-rendered result list this session (JS-driven form). The German EudraCT TIPP record (2021-000190-81) was retrieved (HTTP 200); the trial-status field was not in the server-rendered HTML, so the prior Temporarily Halted versus published-end discrepancy is preserved rather than updated.
What survived triage: seven bibliography additions, taking the bibliography to 432 distinct PMIDs. Newly returned since 22 October: Rink 2026 (PMID 42936732), Pedersen 2026 (PMID 42933820), Alsufyani 2026 (PMID 42904911), Poulos 2026 (PMID 42950894), Chaudhuri 2026 (PMID 42918296) and Greig 2026 (PMID 42918302). Boakye-Dankwa 2026 (PMID 42242757; ERJ, epublished 22 October) was not in the previous sweep’s ID list and is a within-window catch-up. Most of the 1,009 records deserved nothing. Reliever, formulation, exploratory, preclinical and small qualitative papers were not promoted. Mendoza 2026 (PMID 42914010) had an empty abstract in PubMed and Europe PMC and was omitted. Saint-Pierre 2026 (PMID 42904223) is a 75-person retrospective tezepelumab series confirmatory of NAVIGATOR. No landmark note was warranted.
Source-checked clinical changes: Boakye-Dankwa’s full-text Table 2 (PMC13687804) shows RCT-style type-2, smoking and exacerbation criteria modify the CHRONICLE biologic–exacerbation association while spirometry-based exclusions do not; added to the trials landscape and OQ-16. Rink’s SHARP Tables 1–2 (PMC13701127) document European severe-asthma comorbidity capture and MDT gaps; added to comorbidity (previously untouched) and OQ-21. Pedersen’s COPSAC analysis (PMC13711545) associates an IQR of postnatal PM2.5 with lower age-6 FEV1 and higher airway resistance; added to genetics/environment and OQ-6. Alsufyani’s rhinitis-treatment review was added to comorbidity as abstract-level (GRADE moderate for symptoms only). Poulos’s imputed Australian community biomarker prevalences entered the statistics register as abstract-level. Chaudhuri (REALITI-A OCS post hoc) and Greig (n=24 dupilumab interval prolongation) remain bibliography-only.
Retraction and full-text checks: all seven added papers were checked against live PubMed publication types and Crossref updated-by; none had a retraction or expression-of-concern signal and all seven Crossref lists were empty. Fukuda’s protocol DOI was checked the same way. Opened full text for Boakye-Dankwa, Rink and Pedersen; cited tables/limitations match the retrieved text. Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset; Crossref received no mailto.
ClinicalTrials.gov: re-fetched all 22 previously cited IDs plus CHRONICLE (NCT03373045) through API v2. No recruitment-status change and no new results postings versus 22 October; NIMBLE and PERFORM already had results. NCT06748053 was updated 2026-10-26 and remains active, not recruiting, with primary completion still 2026-07-14 and no results. GATA-3 (NCT05254314) still has no results after 2026-09-28 primary completion. Dupilumab withdrawal (NCT06818019) remains recruiting with no results. The corpus now cites 23 NCT IDs.
Guidelines: retrieved GINA reports (2026 Strategy, Summary Guide and Severe Asthma Guide still current; 23 October executive-summary news is the already-catalogued PMID 42847657), NICE NG245 history (still 27 November 2024), Australian Handbook homepage, NHLBI 2020 focused updates, and AAAAI’s parameter list (cookie/JS; anticipated severe-asthma parameter still not readable as a published document). No new comprehensive edition. WHO fact sheet re-opened: still 28 April 2026, 363 million affected and 442,000 deaths in 2023.
Statistics and patient organizations: WHO numbers unchanged, so the existing row was rechecked rather than rewritten. CDC FastStats again returned HTTP 403; the 22 October CDC figures were not refreshed. Retrieved AAFA, Asthma Capitals (already catalogued), GAAPP, Asthma + Lung UK, Asthma Australia; Allergy & Asthma Network news and Asthma Canada returned 403. No new patient-voice theme or private patient detail was added.
Regional limits: SciELO and LILACS could not be searched (HTTP 403 documented in SOURCES.md, not re-probed); no unqualified conclusion about regional transportability is drawn. CENTRAL, Embase, Scopus and Web of Science were not searched. The WHO ICTRP form did not yield a result list this session.
Files changed: trials landscape, comorbidity and mimics, and genetics/environment wiki pages; bibliography; statistics register; OPEN-QUESTIONS; INDEX; this log; and the legal dated sweep manifest. All three edited wiki pages have last-curated: 2026-10-29 and status: draft; comorbidity and genetics/environment are newly demoted. The condition now has six curated and twelve draft pages. Guideline registry and patient-voice files were not edited. Prior audit issues remain pending; no page was promoted and no independent audit is claimed.
Verification: all seven new bibliography PMIDs resolve in this session’s live PubMed cache and have empty Crossref updated-by lists; three full-text quotations match retrieved tables/limitations; inline PMIDs on the three edited wiki pages have matching page references; 432 distinct bibliography PMIDs; page lengths remain 193–247 lines. The manifest maps to the published sweeps/2026-10-29.json path. No global build, publishing script or git command was run. This does not replace the separate clinical audit.
Next sweep / independent audit: audit the October sweep changes (now three engines’ edits) and retain the 15 October metadata/citation audit queue; obtain Srivali’s withdrawal-review full text and Mendoza 2026’s abstract/full text if they appear; retry Roy/Scheire full text; monitor GATA-3 results, NCT06748053 results, dupilumab withdrawal, WRAPT recruitment from 2026-11-09, and NCT06902766’s July 2027 milestone; chase the AAAAI/ACAAI severe-asthma practice parameter through a readable source; check the forthcoming WHO primary-care guideline in early 2027; retry EudraCT TIPP status as readable HTML; continue qualifying regional-evidence limitations while SciELO/LILACS and CENTRAL remain unreachable. OQ-6, -16 and -21 were sharpened, OQ-17’s registry observation refreshed, and no question was closed.